SCHEMBL6550110

SCHEMBL6550110

CC(C)OC(C=O)CCCC(=O)NC(CC(O)c1ccccc1)N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C19 P33261 2/20 0.41
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
NFKB1 P19838 1/20 0.41
MAPK1 P28482 1/20 0.41
HIF1A Q16665 1/20 0.41
UGCG Q16739 1/20 0.41
MTOR P42345 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GMNN O75496 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CERT1 Q9Y5P4 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549347 0.89 MEN1 (0.43) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6548271 0.88 KMT2A (0.45) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6549353 0.81 MEN1 (0.44) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6548227 0.79 LMNA (0.45) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6549071 0.73 KMT2A (0.41) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6549109 0.70 LMNA (0.44) KMT2ACYP3A4CYP2C19MAPTLMNA
SCHEMBL6548444 0.70 POLB (0.47) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6547904 0.69 MEN1 (0.48) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6549283 0.68 SMN1; SMN2 (0.45) KMT2AMEN1CYP3A4CYP2C19MAPT
SCHEMBL6547253 0.66 KMT2A (0.44) KMT2AMEN1CYP3A4CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1106609-B1 Aminoalcohol derivative and medicament comprising the same SEIKAGAKU KOGYO CO LTD (JP) 2004-12-01 EP disclosed
US-6407064-B2 A MORPHOLINO RING CONTAINING ALKYLAMINOALCOHOL DERIVATIVE OR SALTS USEFUL FOR TREATING NEURONAL DISEASES AND AN AGENT FOR PROTECTING BRAIN SEIKAGAKU CORPORATION (JP) 2002-06-18 US disclosed
US-20010003741-A1 Aminoalcohol derivative and medicament comprising the same SEIKAGAKU CORPORATION (JP) 2001-06-14 US disclosed
EP-1106609-A2 Aminoalcohol derivative and medicament comprising the same SEIKAGAKU CORPORATION (JP) 2001-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003741-A1 Aminoalcohol derivative and medicament comprising the same SGMS2, FABP7, SGMS1 KMT2A 2489/4885MEN1 2933/4885CYP3A4 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.